HuagongsheHuagongshe Chemistry Print Report · For research reference only
Piperazine → 5-{-4-[4-(2,4-Dichloro-phenyl)-2-(4'-piperazin-1-yl-biphenyl-4-ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | Piperazine | HCID 4837 | — |
| Reactant | HCID 68583065 | HCID 68583065 | — |
| Product | 5-{-4-[4-(2,4-Dichloro-phenyl)-2-(4'-piperazin-1-yl-biphenyl-4-ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide | HCID 59305538 | — |
Reaction Steps
5-{4-[2-(4′-Bromo-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide (268 mg, 0.4 mmol) was treated as described in general procedure R using excess piperazine (346 mg, 4 mmol) to give the desired compound 5-{4-[4-(2,4-dichloro-phenyl)-2-(4′-piperazin-1-yl-biphenyl-4-ylmethyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US07723369B2 |
| Source dataset | uspto-grants-2010_05 |
| ORD ID | ord-bd98084d83c94a1ea0f415de58db572f |
| Source note | uspto-grants-2010_05 |